Last reviewed · How we verify
ANAVEX2-73 oral liquid
ANAVEX2-73 oral liquid is a sigma-1 receptor agonist Small molecule drug developed by Anavex Life Sciences Corp.. It is currently in Phase 2 development for Alzheimer's disease, Parkinson's disease. Also known as: Blarcamesine.
ANAVEX2-73 is an oral liquid formulation of a sigma-1 receptor agonist.
ANAVEX2-73 is an oral liquid formulation of a sigma-1 receptor agonist. Used for Alzheimer's disease, Parkinson's disease.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ANAVEX2-73 oral liquid |
|---|---|
| Also known as | Blarcamesine |
| Sponsor | Anavex Life Sciences Corp. |
| Drug class | sigma-1 receptor agonist |
| Target | sigma-1 receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
Sigma-1 receptor agonists are a class of compounds that activate the sigma-1 receptor, a protein involved in various cellular processes. ANAVEX2-73 is being investigated for its potential therapeutic effects in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.
Approved indications
- Alzheimer's disease
- Parkinson's disease
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
- ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome (PHASE2, PHASE3)
- ANAVEX2-73 Study in Patients With Rett Syndrome (PHASE3)
- Study of ANAVEX2-73 in Patients With Rett Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ANAVEX2-73 oral liquid CI brief — competitive landscape report
- ANAVEX2-73 oral liquid updates RSS · CI watch RSS
- Anavex Life Sciences Corp. portfolio CI
Frequently asked questions about ANAVEX2-73 oral liquid
What is ANAVEX2-73 oral liquid?
How does ANAVEX2-73 oral liquid work?
What is ANAVEX2-73 oral liquid used for?
Who makes ANAVEX2-73 oral liquid?
Is ANAVEX2-73 oral liquid also known as anything else?
What drug class is ANAVEX2-73 oral liquid in?
What development phase is ANAVEX2-73 oral liquid in?
What are the side effects of ANAVEX2-73 oral liquid?
What does ANAVEX2-73 oral liquid target?
Related
- Drug class: All sigma-1 receptor agonist drugs
- Target: All drugs targeting sigma-1 receptor
- Manufacturer: Anavex Life Sciences Corp. — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Alzheimer's disease
- Indication: Drugs for Parkinson's disease
- Also known as: Blarcamesine